#myelodysplastic-syndrome

Medecine

Diagnostic Histopathology of Tumors E-Book

Christopher D. M. Fletcher

Medecine

Hematopathology E-Book

Elaine Sarkin Jaffe, Nancy Lee Harris, James Vardiman, Elias Campo, Daniel A. Arber

Medecine

Blood and Bone Marrow Pathology E-Book

Anna Porwit, Jeffrey Mccullough, Wendy N Erber

Medecine

Current Clinical Medicine E-Book

Cleveland Clinic

Medecine

Pediatric Allergy: Principles and Practice E-Book

Donald Y. M. Leung, Hugh Sampson, Raif Geha, Stanley J. Szefler

Savoirs

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome

Májek Pavel, Reicheltová Zuzana, Suttnar Jiå™Í, Äœermák Jaroslav, Dyr

Savoirs

Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia

Májek Pavel, Reicheltová Zuzana, Suttnar Jiå™Í, Äœermák Jaroslav, Dyr

Savoirs

Novel C16orf57mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations

Bazan, Negri Gloria, Gervasini Cristina, Elcioglu, Yucelten Deniz, Altunay Ilknur, Cetincelik Umram, Teti Anna, Luciani Matteo, Volpi Ludovica, Larizza Lidia, Del, Sullivan, Yan, Colombo

Savoirs

Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes

Vido, Lorand-Metze, Metze, Metze Konradin, Adam

Savoirs

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

Galimberti Sara, Guerrini Francesca, Salvi Flavia, Petrini Iacopo, Gioia Daniela, Messa Emanuela, Palumbo, Cilloni Daniela, Petrini Mario, Levis Alessandro, Levis

Savoirs

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Wei Guoqing, Ni Wanmao, Chiao Jen-Wei, Cai Zhen, Huang He, Liu Delong, Liu

Savoirs

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Lyons, Larson, Gandhi Sunil, Liu Delong, Matei Carmen, Scott Bart, Hu Kuolung, Wang, Yang